As GSH is an important co-factor of GPX4 activity, GSH depleting drugs, such as those that reduce cysteine availability or GSH synthesis (e.g., erastin, L-buthionine sulfoximine), efficiently promote ferroptosis and even enhance the effectiveness of standard anti-cancer drugs [7,11]. Here, GPX4 is linked to cancer.